Viscosupplementation vs. Corticosteroid Therapy: Clinical Criteria in Knee Osteoarthritis Management 

The easiest mistake in knee OA management is treating injections as interchangeable tools you reach for whenever a patient shows up in pain. They’re not interchangeable, and the two options aren’t even trying to do the same job.

Corticosteroids have a fairly narrow, well-defined purpose: short-term pain and inflammation control. Viscosupplementation is a murkier proposition. The evidence is mixed, the guidance is cautious, and its place in practice is a lot smaller than the marketing around hyaluronic acid products sometimes suggests.

I’d start the decision differently than most clinicians do. Instead of asking which injection to use, ask what the patient actually needs from an injection right now. That’s a small reframe, but it changes almost everything downstream.

Start With the Patient

A patient with a painful flare after months of stable symptoms is a different clinical picture than one with persistent discomfort despite exercise, weight management, topical treatment, and oral analgesics that just haven’t done enough.

Corticosteroid therapy usually fits the first case better. The ACR gives intra-articular glucocorticoid injections a strong recommendation for knee OA, with evidence backing short-term gains in pain and function.

Hyaluronic acid sits in a more complicated spot. AAOS doesn’t recommend routine use for symptomatic knee OA. ACR conditionally recommends against it too, though both leave room for cases where a patient and clinician decide it’s still worth trying after other options have fallen short. There’s no clean winner here. There’s a clinical context, and it depends heavily on what’s already been tried.

What Each Injection Is Actually Trying to Do

People often lump corticosteroids and hyaluronic acid together because both go into the joint. But the intended role of each is different enough that grouping them obscures more than it explains.

Corticosteroids are anti-inflammatory. When pain is significant and inflammation is contributing to it, the immediate goal is symptom reduction, full stop.

Viscosupplementation uses hyaluronic acid, a substance naturally present in synovial fluid. It’s generally considered after conservative measures haven’t provided enough relief, not as a first move.

Hyalgan is one example, a sodium hyaluronate product indicated for knee OA pain in patients who haven’t responded adequately to conservative non-drug treatment and simple analgesics. Its prescribing information also flags specific contraindications: hypersensitivity to hyaluronate preparations, and injection into a site affected by infection or skin disease. Worth sitting with that for a second, because choosing a viscosupplement isn’t really a matter of deciding whether hyaluronic acid “sounds right” for a patient. The patient has to fit the indication. The specific product has to fit the situation. Those are two separate checks, and skipping either one is how selection mistakes happen.

That table exposes something people miss: a viscosupplement doesn’t need to outperform a corticosteroid across every row to have a legitimate place in practice. It needs to fit a specific patient once the evidence, alternatives, risks, and expectations have actually been weighed, not assumed.

Where Hyalgan Fits, and Where It Doesn’t

Once viscosupplementation is genuinely on the table, product selection is a separate decision from the treatment decision. Hyaluronic acid products differ in formulation, molecular weight, concentration, dosing schedule, and source, and those differences matter for practices deciding what to stock.

For practices evaluating sodium hyaluronate options, you can buy Hyalgan for orthopedic practice use to review the product line and purchasing details before a procurement decision. That page is useful for exactly that, checking product specifics. It’s not a reason to prescribe viscosupplementation, and it shouldn’t be treated like one. A product sitting in a supply closet doesn’t make every knee OA patient a candidate for it. The clinical call still belongs to the clinician and the patient, in that order, before procurement enters the picture at all.

When Corticosteroids Have the Stronger Case

Say a patient has established knee OA, meaningful pain, and limited function despite a reasonable conservative plan. The goal is relief over the next few weeks, not months. This is corticosteroid territory. ACR backs intra-articular glucocorticoids with a strong recommendation here, and they’re the default when patients need short-term control and other measures haven’t gotten them there.

An injection still shouldn’t replace the rest of the plan, though. Strengthening the muscles around the knee helps function. Weight management matters for patients carrying excess weight. Topical and oral NSAIDs have their own established roles for the right patients.

One thing worth raising with patients on repeated corticosteroid injections: frequency isn’t free. There are open questions about possible structural effects from repeated exposure, and the evidence isn’t fully settled either way. That doesn’t make corticosteroids the wrong choice. It means repeated use should be a reasoned decision each time, not a reflex whenever a patient calls back in pain.

When Viscosupplementation Enters the Conversation

Here’s where I’d personally be more conservative than some colleagues.

If exercise, appropriate medication, and other conservative measures haven’t done enough, and corticosteroids either aren’t suitable or didn’t deliver satisfactory relief, viscosupplementation can reasonably come up. But the conversation with the patient needs to be honest about where the evidence actually stands, not where a product brochure implies it stands.

AAOS doesn’t recommend routine hyaluronic acid injections for symptomatic knee OA. ACR recommends against routine use too, partly because the apparent benefit shrinks considerably once you exclude studies with a higher risk of bias. Patients should hear that plainly, not have it softened into “some studies show benefit.”

A carefully selected patient who understands the uncertainty, and still wants to try another intra-articular option, is a reasonable candidate for shared decision-making. What it shouldn’t become is a way to promise cartilage regeneration or an OA reversal. The realistic goal is symptom management, nothing more dramatic than that.

Deciding Between Them

Three things are worth working through before picking an injection, though not necessarily in a tidy checklist. What’s the actual timeline the patient needs relief on? If it’s weeks, corticosteroids have the stronger evidence base, and there’s not much ambiguity there.

What’s already been tried, and how did the patient actually respond? An injection isn’t supposed to be the first response to every painful knee, and reviewing exercise, physical therapy, weight management, prior injections, and how each one went tells you more than any guideline table will.

And does the patient actually understand what they’re choosing? Someone picking viscosupplementation needs to understand the benefit is uncertain in magnitude. Someone picking corticosteroids needs to understand how long relief typically lasts and what repeated use might mean down the line. Those conversations do more work than presenting either injection as the obviously superior choice.

A few selection mistakes come up often enough to flag directly. Choosing based on how a treatment worked for a different patient is one, since that tells you almost nothing about this patient. Confusing statistical improvement with meaningful improvement is another, particularly relevant to hyaluronic acid given how cautious the guidelines already are. And skipping product-specific contraindications, Hyalgan’s hypersensitivity and infection-site warnings included, is a check that has to happen before administration, not as an afterthought once a product’s already chosen.

Letting procurement drive care is probably the most avoidable mistake of the bunch. Stocking a product and then finding a patient to justify it is backwards. Patient selection comes first, every time.

The Less Exciting Answer Is Usually the Right One

There’s no need to turn this into a contest between the two. Corticosteroids have the clearer, better-supported role for short-term symptom relief in knee OA. Hyaluronic acid has a narrower, more debated role, one that AAOS and ACR both caution against using routinely.

For the right patient, though, viscosupplementation is still worth discussing. That decision should rest on how they’ve responded to prior treatment, how severe their symptoms are, what contraindications apply, what they actually expect from the injection, and an honest read of what the evidence does and doesn’t show.

For clinicians weighing a specific hyaluronic acid product, the order of operations is simple even if the decision isn’t: assess the patient first, review the product second. Don’t let those two steps swap places.